The potential impact of the hypovitaminosis D on metabolic complications in obese adolescents - Preliminary results

• Published in: Annals of Agricultural and Environmental Medicine 2017-12, Vol.24 (4), p.636-639
• Main Authors: Wojcik, Malgorzata, Janus, Dominika, Kalicka-Kasperczyk, Anna, Sztefko, Krystyna, Starzyk, Jerzy B
• Format: Article
• Language: English
• Subjects: Adolescent; Adolescents; arterial hypertension; Biochemical tests; Blood Pressure; Child; Fatty liver; Female; fibroblast growth factor 19; Fibroblast growth factor 23; Fibroblast Growth Factors - blood; Fibroblasts; Growth factors; Humans; Hypertension; Hypovitaminosis D; Male; Metabolism; Obesity; Obesity - blood; Obesity - complications; Phosphorus; Poland; Prevalence; Steatosis; Teenagers; Uric Acid; Uric Acid - blood; Vitamin D; Vitamin D - blood; Vitamin D Deficiency - blood; Vitamin D Deficiency - etiology; Vitamin D Deficiency - physiopathology; Vitamin deficiency
• ISSN: 1232-1966; 1898-2263
• DOI: 10.5604/12321966.1230676

Vitamin D deficiency is common in obesity; however, its contribution in the development of metabolic complications remains uncertain. The aim of the study was to examine the relationships between vitamin D status and metabolic complications. The results of blood pressure measurements, biochemical tests and ultrasound of the liver were compared in both groups. The study was conducted at the Children's University Hospital in Krakow, Poland. 30 obese adolescents (mean 13.23y.o.); 18 with 25OHD levels 20 ng/mL. The vitamin D deficient group presented with significantly higher values of the diastolic blood pressure (125.9vs.115mmHg), uric acid level (384.7vs.301.5umol/L) and lower phosphorus level (1.4vs.1.65mmol/L), higher prevalence of arterial hypertension (44vs.8.3%), and liver steatosis (25vs.8.3%); lower, but not significantly, levels of fibroblast growth factor 23 and fibroblast growth factor 19. Hypovitaminosis D in obese adolescents is associated with higher prevalence of arterial hypertension, liver steatosis, elevated serum uric acid and low phosphorus levels. The potential contribution of the fibroblast growth factor 23 and fibroblast growth factor 19 in these complications development needs further investigation.